-+ 0.00%
-+ 0.00%
-+ 0.00%

*Vor Biopharma: Enrollment on Track for Phase 3 UPSTREAM MG Trial of Telitacicept in Generalized Myasthenia Gravis Patients With Topline Results Anticipated in 1H27 >VOR

Dow Jones·05/13/2026 12:33:00

Please log in to view news